- Research article
- Open Access
ERK is a negative feedback regulator for IFN-γ/STAT1 signaling by promoting STAT1 ubiquitination
BMC Cancer volume 18, Article number: 613 (2018)
We recently reported that STAT1 plays a tumor suppressor role, and ERK was inversely correlation with STAT1 expression in esophageal squamous cell carcinoma (ESCC). Here, we investigated the mechanism(s) that are responsible for the ERK regulates STAT1 in ESCC.
We performed the immunoprecipitation (IP) to detect the ubiquitin of STAT1 upon MEK transfection or U0126 treatment and co-IP to confirm the binding of STAT1 and ERK in ESCC cell lines.
We found evidence that the ubiquitin-proteasome pathway can efficiently degrade STAT1 in ESCC cells, as MG132 treatment rapidly and dramatically increased STAT1 expression in these cells. This process is not dependent on the phosphorylation of the two important STAT1 residues, Y701 and S727, as site-directed mutagenesis of these two sites did not affect STAT1 degradation. We also found that ERK promotes proteasome degradation of STAT1, supported by the observations that pharmacologic inhibition of ERK resulted in a substantial increase of STAT1 whereas expression of constitutively active ERK further reduced the STAT1 protein level. In addition to suppressing STAT1 expression, ERK limited STAT1 signaling by decreasing the production of IFNγ.
To conclude, ERK is an effective negative regulator of STAT1 signaling in ESCC, by promoting its proteasome degradation and decreasing IFNγ production. Our data further supports that targeting ERK and/or STAT1 may be useful for treating ESCC.
Esophageal squamous cell carcinoma (ESCC) is one of the leading cancer worldwide, especially China . Chaoshan area is the highest age-standardized incidence area in China . The growth of ESCC is regulated via a complex network of signal transduction pathways.
The JAK-STAT (Signal transducers and activators of transcription) signaling pathway has been identified as a potential target for novel cancer therapies. STAT1 is a critical mediator of cytokine signaling . STAT1 is a key mediator in gamma-interferon (IFNγ) signaling, which activates STAT1 by its phosphorylation. STAT1 has been reported as a tumor suppressor in breast cancer, multiple myeloma and leukemia . We previously reported that STAT1 can promote ESCC cell apoptosis and inhibit cell growth and the STAT1low expression patients in ESCC significantly correlates with a worse clinical outcome [5, 6]. Extracellular regulated protein kinases (ERK), a key regulator of mitogen-activated protein kinase (MAPK) signaling pathway, functions as an important anti-cancer therapeutic target in multiple malignant tumors, such as breast cancer, esophageal cancer . In our previous research, we found that ERK can negative regulate STAT1 in ESCC and expression of ERK/p-ERK is adversely correlated with STAT1 expression. The ESCC patients with ERK low/STAT1 high had the longest survival compared with other patients .
The function of the ubiquitin-proteasome pathway (UPP) involves removing damaged and redundant proteins from the cells. This process occurs in the regulation of several cellular processes, including cell proliferation, cell death, cell division, DNA repair, and cell differentiation . Aberrations of this pathway occur in the pathogenesis of various human diseases, especially chronic inflammatory diseases and neurodegenerative disorders, even cancer . Proteasome inhibitors have emerged as a novel chemotherapeutic agent for treating cancers. The peptide-aldehyde proteasome inhibitor MG132 (carbobenzoxyl-L-leucyl-L-leucyl-L-leucine), inhibiting 20S proteasome activity and effectively blocking the proteolytic activity of the 26S proteasome complex, has been reported to induce tumor cell apoptosis and thus it plays a crucial role in anti-tumor treatment .
In this study, the main purpose is to delineate the mechanisms by which IFN/STAT1 signaling is down-regulated by ERK in ESCC. In this study, we identified that ERK is a key regulator of STAT1, by means of promoting its proteasomal degradation and decreasing the production of IFNγ.
Human ESCC cell lines EC1 and KYSE150, were used in this study. EC1 cell lines was purchased from Hongkong University in 2011 and KYSE150 was purchased from DSMZ in 2012. They were maintained in RPMI 1640 or Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA). All cells were verified to be free of mycoplasma contamination.
siRNA, plasmid constructs and drugs
STAT1 siRNA and scramble RNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Transfection of siRNA was performed using Lipofectamine RNAimax (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Plasmids including eGFP-STAT1, eGFP-STAT1Y701F, eGFP-STAT1S727A, Flag-STAT1β were purchased from Addgene (Cambridge, MA, USA). Flag-tagged, constitutive-active STAT1 (or STAT1C) cloned into the backbone of pcDNA3.1 was a gift from Dr. Toru Ouchi (Roswell Park Cancer Institute, University at Buffalo, NY, USA). The constitutively active MEK-1 (HA-ca-MEK) vector was a gift from Dr. Nathalie Rivard (Université de Sherbrooke, Québec, CA). The proteasome inhibitor N-carbobenzoxyl-L-leucinyl-L-norleucinal (MG132) was purchased from Calbiochem (La Jolla, CA, USA) and 5-Aza-2′-deoxycytidine (5-Aza) was purchased from Sigma (St Louis, MO, USA). U0126, a Mitogen-activated protein kinase 1 (MEK1) inhibitor was purchased from Sigma (St Louis, MO, USA).
Co-immunoprecipitation, immunoprecipitation and western blot analysis
Co-immunoprecipitation, immunoprecipitation and Western blot analysis were performed as described previously . Antibodies reactive with human β-actin, caspase-9, caspase-3, Bcl-2, Bcl-xL, STAT1, phospho-STAT1 serine 727 (or p-STAT1 S727), phospho-STAT1 tyrosine 701 (or p-STAT1 Y701), phospho-ERK (or p-ERK), ERK, Ubiquitin (or Ub), phospho-JAK2 (or p-JAK2), JAK2, Human influenza hemagglutinin (or HA) and Poly ADP ribose polymerase (PARP) were purchased from Cell Signaling.
Cell growth and Colony formation assay
To evaluate the effect of MG132 on the growth of ESCC cell lines, cell viability was determined by using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, Madison, WI) and trypan blue assay (sigma, St Louis, MO, USA) according to the manufacturer’s protocol. Colony formation assay was performed as described previously .
Using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), total cellular RNA was extracted from cells following the manufacturer’s protocol. Primer sequence for IFNγ is: Forward: 5′- TGACCAGAGCATCCAAAAGA-3′, Reverse: 5′-CTCTTCGACCTCGAAACAGC-3′. IFNγ receptor: Forward: 5′-TCTTTGGGTCAGAGTTAAAGCCA-3′, Reverse: 5′-TTCCATCTCGGCATACAGCAA-3′. Human GAPDH was used as control.
Immunofluorescence and confocal microscopy
Immunofluorescence was performed as previously described . Cells were visualized with a Zeiss LSM 710 confocal microscope at the Core Cell Imaging Facility, Cross Cancer Institute, Alberta, Canada.
Apoptosis was measured by using the FITC-conjugated Annexin V/PI assay kit (Invitrogen, Carlsbad, CA, USA) and flow cytometry. After treatment with scramble RNA or siRNA STAT1 for 24 h, cells were treated with 10 μM MG132 for 24 h and then collected according to the manufacturer’s protocol.
Enzyme-linked immunosorbent assay (ELISA)
The supernatant of cell suspension from harvested cells were collected, the level of IFNγ was analyzed by ELISA using the commercially available ELISA kits in a 96-well microplate (eBioscience, San Diego, CA, USA) at an optical density of 450 nm, according to the manufacturer’s protocol.
Analysis of ESCC data in cBioportal for cancer genomics database
The cBioPortal for Cancer Genomics is an open-access downloaded bio-database, providing visualization and analyzing tool for large-scale cancer genomics data sets (www.cbioportal.org). This portal collected records that were derived from 147 individual cancer studies, in which 31 types of cancer were analyzed, which included over 21,000 samples. Analysis of the 185 esophageal cancer samples from this database was performed in silico.
Data was expressed as mean ± standard deviation. The prognostic significance of the expression of various markers was analyzed using the Kaplan Meier’s analysis. Differences among the treatment groups were assessed using ANOVA and the appropriate statistical software (SPSS, IBM, USA). A p-value of ≤0.05 was considered as statistically significant.
MG132 increases the protein expression of STAT1 in ESCC cell lines
To investigate the mechanism(s) by which STAT1 is down-regulated in ESCC, we questioned if the STAT1 gene is silenced via gene methylation. Thus, we treated two ESCC cell lines EC1 and KYSE150 with 1–10 μM 5-Aza for 0–48 h. By Western blots and quantitative RT-PCR, we did not find any appreciable change in STAT1 nor phospho(p)-STAT1 expression, suggesting that gene methylation does not play a role in suppressing STAT1 expression in ESCC (Additional file 1: Figure S1).
In view of one previous report that STAT1 can be degraded via the ubiquitin-proteosome pathway in mouse embryonic fibroblasts , we tested if this mechanism contributes to the low expression level of STAT1 in ESCC. Thus, we treated EC1 and KYSE150 with varying concentrations (1–10 μM) of MG132 for 24 h. By Western blots, we found that the STAT1 protein level in all cell lines was dramatically up-regulated in a dose-dependent manner, and this STAT1 up-regulation was detectable at an MG132 concentration as low as 1 μM (Fig. 1a). Furthermore, MG132 induced an increase in STAT1 in time-dependent manner (Fig. 1b). With the exception of EC1, a cell line that did not express p-STAT1S727, the STAT1 phosphorylation level at Y701 and S727 generally increased in parallel with the total protein level of STAT1. These findings suggest that there are mechanism(s) that constitutively activate STAT1 in ESCC cells at the steady state.
ERK promotes polyubiquitination of STAT1 independent of STAT1 phosphorylation
We performed immunoprecipitation and Western blots to detect STAT1 ubiquitination in EC1 and KYSE150 cells. As shown in Fig. 2a, STAT1 ubiquitination was decreased in the presence of U0126 compared to the negative controls. Moreover, transfection of the constitutively-activated MEK/ERK plasmid increased STAT1 polyubiquitination, compared with the empty vector (Fig. 2b). Taken together, these results support the concept that ERK activation promotes polyubiquitination and proteasomal degradation of STAT1.
As mentioned, one previous study using mouse embryonic fibroblasts has shown that ERK phosphorylates STAT1 at S727 and targets it for proteasomal degradation . To determine whether the two phosphorylation sites of STAT1 (Y701 and S727) contribute to STAT1 polyubiquitination, we transfected plasmids encoding GFP-tagged STAT1 or the two STAT1 mutants (S727A and Y701F) into the EC1 cells, and the results are illustrated in Fig. 2c. As expected, treatment of U0126 effectively decreased the amount of p-ERK, and this change correlated with a reciprocal increase in GFP and STAT1 proteins. The levels of both STAT1S727A and STAT1Y701F increased in response to the U0126 treatment. In addition, silencing of ERK by inhibitor U0126 decreased the polyubiquitination of STAT1, either in the form of wild-type and mutants (Fig. 2d). These findings suggest that the degradation of STAT1 mediated by ERK is independent of the phosphorylation at Y701 or S727. STAT1β is a C-terminal-truncated version of STAT1 that lacks S727, but retains Y701  . To further support the concept that phosphorylation of STAT1S727 is not required for ERK-mediated STAT1 proteasomal degradation, we transfected Flag-tagged STAT1α and STAT1β plasmids into EC1 cells with or without U0126. As shown in Fig. 2e, we found that U0126 can increase both exogenous STAT1α and STAT1β in both cell lines; in addition, ERK can promote the polyubiquitination of both STAT1α and STAT1β (Fig. 2f). These results further support that active ERK can mediate STAT1 degradation that is independent of the phosphorylation of S727.
ERK binds to STAT1 in ESCC
To further delineate the mechanisms underlying ERK-mediated STAT1 proteasomal degradation, we examined whether ERK binds to STAT1. Co-immunoprecipitation experiments were performed using EC1 and KYSE150 cells, with or without MG132 treatment. As shown in Fig. 3a, immunoprecipitation of ERK pulled down STAT1 in both cell lines, and MG132 treatment appreciably increased the amount of STAT1 bound to ERK, probably due to the fact that the total amount of STAT1 increased in response to proteasomal inhibition by MG132. Reciprocal pull-down experiments showed essentially the same results, except that we did not see a MG132-induced increase in the amount of ERK bound to STAT1, probably due to the fact that the protein level of ‘bioavailable’ STAT1 was substantially lower than that of ERK. Moreover, the co-localization of ERK and STAT1 was confirmed by confocal microscopy (Fig. 3b). To determine whether the phosphorylation status of STAT1 is required for the ERK-STAT1 interaction in ESCC cells, we transfected EC1 cells with wild-type STAT1, STAT1Y701F or STAT1S727A. All of the plasmids used were GFP-tagged. Results are illustrated in Fig. 3c. ERK was pulled down along with STAT1 as well as STAT1 mutants. These results indicated that STAT1 can bind to ERK independent of the phosphorylation status of STAT1 at the Y701 or S727, two sites known to be important for the function of STAT1. These findings are in parallel with the previous experiments in which we showed that ERK can mediate STAT1 degradation independent of the two STAT1 phosphorylation sites mutants.
ERK is a negative feedback regulator for IFN-γ/STAT1 signaling
The ERK signaling pathway has been reported to play a crucial role in IFNγ/STAT1 signaling in human macrophages . We hypothesized that, in addition to decreasing STAT1 expression, ERK may further down-regulate STAT1 signaling by suppressing IFNγ production. Our data is in support of this concept. Using quantitative RT-PCR, we found that inhibition of ERK by U0126 increased the expression of IFNγ and IFNγ receptor in both ESCC cell lines (Fig. 4a). As shown in Fig. 4b, similar results were found when we performed the ELISA to detect the active form of IFNγ. As shown in Fig. 4c, we also found evidence that IFNγ up-regulated p-ERK, which appears to serve as a gatekeeper to prevent over-stimulation of STAT1, which is known to provide potent pro-apoptotic signal in ESCC cells . To demonstrate the effectiveness of ERK in blocking IFNγ-mediated activation of STAT1, we transfected EC1 with the constitutively active ERK vector before the addition of IFNγ to the cell culture. As shown in Fig. 4c, the expression of constitutively active ERK substantially dampened the up-regulation of p-STAT1 induced by IFNγ. Moreover, we performed the colony formation to evaluate the biological effect of ERK on STAT1 in both cell lines. As shown in Fig. 4d, U0126 significantly diminished the clonogenic ability of ESCC cell with STAT1 knockdown by siRNA; at the same time, constitutive-active MEK significantly increased the clonogenic ability of ESCC cells transfected with STAT1C (p < 0.05). Taken together, these findings suggest that ERK is a key regulator of STAT1 function in ESCC cells.
MG132-induced apoptosis in ESCC is STAT1-dependent
The observation that MG132 can induce effective apoptosis in various types of cancer, including ESCC, has been widely published [10, 14]. In view of our findings that STAT1 can induce effective apoptosis in ESCC , and our current observation that proteasome degradation is a key pathway to down-regulate STAT1, we hypothesized that MG132 also induces apoptosis in ESCC via a STAT1-dependent pathway. First, we confirmed that MG132 effectively induced apoptosis in ESCC cells, as evidenced by the reduction of viable cells as well as enhanced the cleavage of caspase 3 and PARP expression in dose and time dependent manner of MG132 treatment (Fig. 5a and b). Second, we found that siRNA knockdown of STAT1 significantly attenuated MG132-induced cell inhibition (at 5 μM) in EC1 and KYSE150 cells (Fig. 5c), and these findings correlated with the the lack of change in caspase 3, PARP and Annexin-V/propodium iodide (Fig. 5d-e). Taken together, these observations suggest that MG132-induced apoptosis in ESCC is highly STAT1-dependent.
The expression and biological correlation between STAT1 and ERK in esophageal cancer
In the previous published papers, we demonstrated the expression of STAT1 and ERK and its correlation with the clinical significance of ESCC patients . Then we further investigate STAT1 and MAPK1(ERK) expression in ESCC. The bioinformatics analysis was performed to detect these gene alterations and expression in ESCC, using cBioportal Web resource online (cBioportal for Cancer Genomic)(Fig. 6a). However, we didn’t find the significance correlation between patients survival and STAT1/ERK alteration (Fig. 6b). As shown in Fig. 6c, the mutual exclusivity and co-occurrence analysis by Cbioportal revealed that STAT1 and ERK have a tendency to occur together. The results from the database supports our previous finding that ERK inhibit STAT1 expression and activation in ESCC and consistent with our previous results that ERK inhibited STAT1 expression .
In this paper, we have reported that the ERK negatively regulated IFN-γ signaling by ubiquitination of STAT1 in ESCC cells. We also found that MG132 induced apoptosis is partly dependent on STAT1activation, since STAT1 siRNA attenuate the apoptosis of ESCC cells.
The main objective of the current study is to identify the mechanism(s) that are responsible for the low expression of STAT1 in ESCC tumors. STAT1 has been reported as a tumor suppressor in multiple cancers by inhibiting tumor cell angiogenesis, tumorigenicity and metastasis . One previous study has shown that reduced STAT1 expression in squamous cell carcinoma of the head and neck is due to gene methylation and silencing of the STAT1 gene . Data from our experiments using 5-Aza does not support that STAT1 downregulation in ESCC was because of gene methylation. Based on another study with MEF cell lines in which ERK can promote STAT1 proteasomal, we also proved that ERK is responsible for the down-regulation of STAT1 in ESCC. In contrast with the model, ubiquitination and proteasomal degradation of STAT1 by ERK in ESCC cells are not dependent on STAT1 phosphorylation at Y701 and S727, two phosphorylation sites known to be functionally important for STAT1.
We also found evidence that mechanisms that constitutively activate STAT1 may exist in ESCC cells, since p-STAT1Y701 increased along with total STAT1 in all 3 ESCC cell lines examined. We believe that this finding carries important therapeutic implications. In view of the fact that STAT1 phosphorylation at tyrosine 701 is required for its dimerization, nuclear translocation and DNA-binding , a restoration of STAT1 expression in ESCC may be sufficient to induce apoptosis. The loss of STAT1 phosphorylation at serine 727 in EC1 but not the other 2 cell lines may have shed important insight into the biological heterogeneity of ESCC. Regarding p-STAT1S727, it is believed to boost the transcriptional activity of STAT1 and it has been implicated to enhance the anti-viral and anti-proliferation function of IFN-γ [18, 19]. While results from a study suggest that phosphorylation of STAT1S727 is dependent on IFN-γ-induced tyrosine phosphorylation of STAT1 , a few other studies have provided contradictory conclusions [21, 22]. This discrepancy may be linked to the observations that phosphorylation of STAT1S727 is mediated by different kinases stimulated by different signals [23,24,25,26,27,28,29,30].
The ubiquitination and degradation of STAT1 has been described in a number of previous studies. Through our literature search, we found that the ubiquitin-proteasome pathway was implicated in the down-regulation of STAT1 activation by IFNγ . It also has been reported that ubiquitination of STAT1 can be modulated in response to viral and parasitic infection [32, 33]. Several E3 ligases are known to mediate the ubiquitination and degradation of STAT1. For example, both STAT-interacting LIM (SLIM) and smad ubiquitination-regulating factor 1 (Smurf1) promote STAT1 ubiquitination and degradation in mouse macrophage cells and HEK293 cells [34,35,36]. In parallel with our observation, SLIM and Smurf1-mediated STAT1 degradation was found to be independent of STAT1 phosphorylation. Furthermore, in mouse embryonic fibroblasts, F-box E3 ligase and βTRCP were reported to promote STAT1 proteasomal degradation that is dependent on STAT1 phosphorylation at S727 .
In addition to promoting the proteasomal degradation of STAT1, our data suggested that ERK dampens STAT1 activation by suppressing the production of IFNγ, which is known to be a potent activator of STAT1. IFNγ is used for treating cancers and viral infection, however, the therapeutic efficacy of IFNγ is highly variable among different types of cancer [37, 38]. For example, while IFNγ appears to be effective in treating adult T cell leukemia and ovarian cancers, it is relatively ineffective for most patients suffering from chronic myeloid leukemia . Moreover, IFNγ-treated melanoma patients were found to have a worse survival than those who did not receive IFNγ . Based on our result, IFNγ might be an effective anti-cancer drug for tumors that lack a high level of expression and/or activation of ERK, and/or express a certain basal level of STAT1 that can be activated.
In this study, we demonstrated that ERK promotes proteasome degradation of STAT1 and down-regulates STAT1 activation by suppressing IFNγ production. We previous found that STAT1 plays a tumor suppressor role in esophageal cancer, and ERK expression was inversely correlated with STAT1. In this study, we further found that ERK promotes tumorigenesis of ESCC by suppressing the expression and activation of STAT1.
Dulbecco’s modified Eagle’s medium
Enzyme-linked immunosorbent assay
Extracellular regulated protein kinases
Esophageal squamous cell carcinoma
Mitogen Activated Protein Kinase
Mouse embryonic fibroblast
Mitogen-activated protein kinase 1
Signal transducers and activators of transcription
Wu C, Kraft P, Zhai K, Chang J, Wang Z, Li Y, Hu Z, He Z, Jia W, Abnet CC, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet. 2012;44(10):1090–7.
Su M, Liu M, Tian DP, Li XY, Zhang GH, Yang HL, Fan X, Huang HH, Gao YX. Temporal trends of esophageal cancer during 1995-2004 in Nanao Island, an extremely high-risk area in China. Eur J Epidemiol. 2007;22(1):43–8.
Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19(3):454–65.
Greenwood C, Metodieva G, Al-Janabi K, Lausen B, Alldridge L, Leng L, Bucala R, Fernandez N, Metodiev MV. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteome. 2012;75(10):3031–40.
Zhang Y, Molavi O, Su M, Lai R. The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer. 2014;14:791.
Zhang Y, Zhang Y, Yun H, Lai R, Su M. Correlation of STAT1 with apoptosis and cell-cycle markers in esophageal squamous cell carcinoma. PLoS One. 2014;9(12):e113928.
Wang H, Zhang Y, Yun H, Chen S, Chen Y, Liu Z. ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma. Oncotarget. 2017;8(28):45249–58.
Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 2004;40(15):2217–29.
Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33–47.
Guo N, Peng Z. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia Pac J Clin Oncol. 2013;9(1):6–11.
Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS, Stephanou A. ERK and the F-box protein betaTRCP target STAT1 for degradation. J Biol Chem. 2008;283(23):16077–83.
Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Bechet JM, Dusanter-Fourt I, Bornkamm GW, Raphael M, Fagard R. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood. 2004;104(8):2475–83.
Li N, McLaren JE, Michael DR, Clement M, Fielding CA, Ramji DP. ERK is integral to the IFN-gamma-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages. J Immunol. 2010;185(5):3041–8.
Dang L, Wen F, Yang Y, Liu D, Wu K, Qi Y, Li X, Zhao J, Zhu D, Zhang C, et al. Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells. Int J Mol Med. 2014;33(5):1083–8.
Huang S, Bucana CD, Van Arsdall M, Fidler IJ. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 2002;21(16):2504–12.
Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, et al. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006;98(3):181–9.
Wenta N, Strauss H, Meyer S, Vinkemeier U. Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci U S A. 2008;105(27):9238–43.
Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M, Decker T. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity. 2003;19(6):793–802.
Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82(2):241–50.
Sadzak I, Schiff M, Gattermeier I, Glinitzer R, Sauer I, Saalmuller A, Yang E, Schaljo B, Kovarik P. Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain. Proc Natl Acad Sci U S A. 2008;105(26):8944–9.
DeVries TA, Kalkofen RL, Matassa AA, Reyland ME. Protein kinase Cdelta regulates apoptosis via activation of STAT1. J Biol Chem. 2004;279(44):45603–12.
Ramsauer K, Sadzak I, Porras A, Pilz A, Nebreda AR, Decker T, Kovarik P. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc Natl Acad Sci U S A. 2002;99(20):12859–64.
Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN, Platanias LC. Activation of protein kinase C delta by IFN-gamma. J Immunol. 2003;171(1):267–73.
Kim HS, Lee MS. Essential role of STAT1 in caspase-independent cell death of activated macrophages through the p38 mitogen-activated protein kinase/STAT1/reactive oxygen species pathway. Mol Cell Biol. 2005;25(15):6821–33.
Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, Cohen P, Decker T. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc Natl Acad Sci U S A. 1999;96(24):13956–61.
Nair JS, Da Fonseca CJ, Tjernberg A, Sun W, Darnell JE Jr, Chait BT, Zhang JJ. Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-gamma. Proc Natl Acad Sci U S A. 2002;99(9):5971–6.
Stephanou A, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight RA, Latchman DS. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem. 2001;276(30):28340–7.
Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem. 2002;277(17):14408–16.
Xu W, Nair JS, Malhotra A, Zhang JJ. B cell antigen receptor signaling enhances IFN-gamma-induced Stat1 target gene expression through calcium mobilization and activation of multiple serine kinase pathways. J Interf Cytokine Res. 2005;25(2):113–24.
Zhu X, Wen Z, Xu LZ, Darnell JE Jr. Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase. Mol Cell Biol. 1997;17(11):6618–23.
Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science. 1996;273(5282):1717–9.
Didcock L, Young DF, Goodbourn S, Randall RE. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol. 1999;73(12):9928–33.
Kubota T, Yokosawa N, Yokota S, Fujii N, Tashiro M, Kato A. Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol. 2005;79(7):4451–9.
Gao C, Guo H, Mi Z, Grusby MJ, Kuo PC. Osteopontin induces ubiquitin-dependent degradation of STAT1 in RAW264.7 murine macrophages. J Immunol. 2007;178(3):1870–81.
Tanaka T, Soriano MA, Grusby MJ. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity. 2005;22(6):729–36.
Yuan C, Qi J, Zhao X, Gao C. Smurf1 protein negatively regulates interferon-gamma signaling through promoting STAT1 protein ubiquitination and degradation. J Biol Chem. 2012;287(21):17006–15.
Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. Ann N Y Acad Sci. 2009;1182:69–79.
Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer. Clin Cancer Res. 2011;17(19):6118–24.
We would like to gratefully acknowledge Dr. Nathalie Rivard (Université de Sherbrooke) for providing the ca-HA-MEK plasmid and Dr. Toru Ouchi (Roswell Park Cancer Institute) for providing the Flag-STAT1C plasmid. We also thank Professor Liyan Xu at the Shantou University Medical College for sharing KYSE150 cells with us.
This study was sponsored by Department of Education of Guangdong (Certificates 2016KQNCX050) and Shantou University Medical College Innovative Training Program (201710560106) awarded to YZ, Guangdong Medical Research funding(A2016516) and Guangdong Self-financing Science Program(NO.5) awarded to ZYL, and an operating research grant from the Canadian Institute of Health Research awarded to RL.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This article does not contain any studies with human participants or animal performed by any of the authors.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1:
Figure S1. The expression of STAT1 in ESCC cell lines has no change via 5-Aza treatments. A. EC1, KYSE150 cell lines were treated with 10 μM of 5-Aza for 24 h, RNA level of STAT1 was analyzed by qRT-PCR. B. EC1, KYSE150 cell lines were treated with 10 μM of 5-Aza for 24 h, Western blot analysis of p-STAT1 and STAT1 in total cell lysates were shown. (JPG 695 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Zhang, Y., Chen, Y., Liu, Z. et al. ERK is a negative feedback regulator for IFN-γ/STAT1 signaling by promoting STAT1 ubiquitination. BMC Cancer 18, 613 (2018). https://doi.org/10.1186/s12885-018-4539-7
- Esophageal squamous cell carcinoma
- Proteasomal degradation